| Target | Drugs | First neighbors |
| EGFR | cetuximab, AEE 788, panitumumab, BMS-599626, ARRY-334543, XL647, canertinib, gefitinib, HKI-272, PD 153035, lapatinib, vandetanib, erlotinib | 125 | PDGRFB | dasatinib, sunitinib, pazopanib, axitinib, KRN-951, tandutinib, imatinib, sorafenib, becaplermin | 61 | ERBB2 | trastuzumab, BMS-599626, ARRY-334543, XL647, CP-724,714, HKI-272, lapatinib, erlotinib | 59 | MET | crizotinib | 55 | ERBB4 | BMS-599626 | 44 | KIT | dasatinib, sunitinib, pazopanib, KRN-951, OSI-930, telatinib, tandutinib, imatinib, sorafenib | 38 | FLT4 | sunitinib, pazopanib, CEP 7055, KRN-951, telatinib, sorafenib, vandetanib | 36 | PDGFRA | sunitinib, pazopanib, axitinib, telatinib, imatinib, becaplermin | 35 | TEK | Vandetanib | 35 | RET | sunitinib, vandetanib | 30 | FGFR1 | Pazopanib | 29 | EPHA2 | Dasatinib | 22 | FGFR3 | Pazopanib | 18 | FLT3 | CHIR-258, tandutinib, sorafenib, lestaurtinib, CGP 41251 | 14 | FGFR2 | Palifermin | 13 |
|
|